key: cord-0078450-o39qn3pk
authors: Rudolphi-Solero, T.; Rashki, M.; Fernández-Fernández, J.; Rivas-Navas, D.; Ramos-Font, C.; Rodríguez-Fernández, A.
title: SARS-COV-2 virus triggers immune antitumor response in a lymphoma patient()
date: 2022-05-23
journal: Rev Esp Med Nucl Imagen Mol (Engl Ed)
DOI: 10.1016/j.remnie.2022.05.007
sha: fa3f3d197fd32ef89ba1b36e33ca5f205bf706d3
doc_id: 78450
cord_uid: o39qn3pk

nan

El virus SARS-COV-2 desencadena una respuesta inmunitaria antitumoral en un paciente con linfoma Rudolphi-Solero, Teodoro a ; Rashki, Mahsa a ; Fernández-Fernández, Javier a ; Rivas-Navas, Daniel a ; Ramos-Font, Carlos a ; Rodríguez-Fernández, Antonio a . a Servicio de Medicina Nuclear del hospital Universitario Virgen de las Nieves, Granada, España

We present a 55-year-old male patient with a follicular lymphoma (stage III-S) diagnosed in 2014. CHOP chemotherapy and Rituximab ended in 2016 with a good response. In 2020 a soft palate mass appeared. This lesion was biopsied and a lymphoid B neoplasm with a nodular pattern was found. Staging [ 18 F]FDG PET/CT found several hypermetabolic lymphatic nodes at cervical, pectoral and iliac regions, with a hard palate mass and other retroperitoneal lesion; so the conclusion was a lymphoma recurrence. The patient started new line treatment with ESHAP chemotherapy.

After 2 cycles of chemotherapy, an interim [ 18 F]FDG PET/CT was performed. The cervical lymphadenopathy and the hard palate mass disappeared. The rest of the lymphadenopathies decreased their metabolic activity. Even the retropancreatic mass reduced its size. The remanings lesions presented the following SUVmax: retropancreatic mass (3,87), pectoral (4,94) and iliac (4,18). The liver SUVmean was 1,87 and the mediastinal blood pool SUVmean was 1,16. The Metabolic Tumor Volume (MTV) was 3,68 cm 3 and the Total Lesion Glycolysis (TLG) was 7,85 SUV-lbm.cm 3 . The next proposed line of treatment was Rituximab. Before the first cycle, the patient suffered from SARS-COV-2 pneumonia and had a corticosteroid treatment, but no immunochemotherapy. One month after the infection, the patient got a negative result for SARS-COV-2 PCR.

Another restaging [ 18 F]FDG PET/CT was performed and the pectoral and iliac lymphadenopathies significantly decreased their metabolic activity rate and size. Also, the retropancreatic mass reduced its size, but kept its metabolic activity rate. The SUVmax of the lesions was: retropancreatic mass (3,44), pectoral (1,93) and iliac (1, 49) . The liver SUVmean was 1,56 and the mediastinal blood pool SUVmean was 1,51. The MTV was 3,00 cm 3 and the TLG was 4,23 SUV-lbm.cm 3 . Additionally, a pulmonary infiltrate with an increase of the metabolic activity was described related to the SARS-COV-2 infection. It was interpreted as a partial response without any therapy. Finally, the Rituximab treatment was initiated.

As mentioned in the medical literature, there is evidence that virus antigens could generate an antitumor activity 1 . There is a low number of reported cases of lymphomas which spontaneously decrease its metabolic activity and size, concurring with a viral infection 2 . The main hypothesis in this case was that the SARS-COV-2 virus triggered an immune response that brought out a cytokines chain which activated an immune cells reaction against the neoplastic cells 3 . 

Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice

Park SI Complete Spontaneous Remission of Diffuse Large B-Cell Lymphoma of the Maxillary Sinus After Concurrent Infections

SARS-CoV-2-induced remission of Hodgkin lymphoma